Last reviewed 2026-06-02 · How we verify

MUC1-peptide-DC-CTL

Beijing Doing Biomedical Co., Ltd. · Phase 1 active Biologic ✓ Verified Jun 2026

MUC1-peptide-DC-CTL is a Biologic drug developed by Beijing Doing Biomedical Co., Ltd.. It is currently in Phase 1 development.

Researchers at Beijing Doing Biomedical Co., Ltd. conducted a Phase 1 study on MUC1-peptide-DC-CTL treatment in stage IV gastric cancer patients. The study aimed to evaluate the clinical safety and preliminary efficacy of this treatment, which involves dendritic cells infected with a recombinant MUC1 gene or peptide.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MUC1-peptide-DC-CTL
Sponsor	Beijing Doing Biomedical Co., Ltd.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MUC1-peptide-DC-CTL CI brief — competitive landscape report
MUC1-peptide-DC-CTL updates RSS · CI watch RSS
Beijing Doing Biomedical Co., Ltd. portfolio CI

Frequently asked questions about MUC1-peptide-DC-CTL

What is MUC1-peptide-DC-CTL?

MUC1-peptide-DC-CTL is a Biologic drug developed by Beijing Doing Biomedical Co., Ltd..

Who makes MUC1-peptide-DC-CTL?

MUC1-peptide-DC-CTL is developed by Beijing Doing Biomedical Co., Ltd. (see full Beijing Doing Biomedical Co., Ltd. pipeline at /company/beijing-doing-biomedical-co-ltd).

What development phase is MUC1-peptide-DC-CTL in?

MUC1-peptide-DC-CTL is in Phase 1.

Manufacturer: Beijing Doing Biomedical Co., Ltd. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing